APA
Kimball A. B., Sobell J. M., Zouboulis C. C., Gu Y., Williams D. A., Sundaram M., Teixeira H. D. & Jemec G. B. E. (20170426). HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. : Journal of the European Academy of Dermatology and Venereology : JEADV.
Chicago
Kimball A B, Sobell J M, Zouboulis C C, Gu Y, Williams D A, Sundaram M, Teixeira H D and Jemec G B E. 20170426. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. : Journal of the European Academy of Dermatology and Venereology : JEADV.
Harvard
Kimball A. B., Sobell J. M., Zouboulis C. C., Gu Y., Williams D. A., Sundaram M., Teixeira H. D. and Jemec G. B. E. (20170426). HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. : Journal of the European Academy of Dermatology and Venereology : JEADV.
MLA
Kimball A B, Sobell J M, Zouboulis C C, Gu Y, Williams D A, Sundaram M, Teixeira H D and Jemec G B E. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. : Journal of the European Academy of Dermatology and Venereology : JEADV. 20170426.